Navigation Links
Abbott to Present New Data Across its Vascular Portfolio at the,,,American College of Cardiology's 56th Annual Scientific Session

p>

EXACT and CAPTURE 2 Carotid Clinical Trial 30-Day Results

Late-Breaking Clinical Trials III, i2. Summit Interventional Programming Monday, March 26, 11:15 a.m. Central Time

Room La Nouvelle Orleans C, Ernest N. Morial Convention Center

Interim results of 30-day clinical follow-up for the first 1,500 patients enrolled in Abbott's EXACT clinical study and the first 600 patients enrolled in CAPTURE 2 will be presented by William A. Gray, M.D., FACC, from the Medical Center in New York. EXACT and CAPTURE 2 are studies designed to confirm that carotid stenting can be performed with good results by a variety of physician specialties in real-world (non-clinical trial) settings in patients who are at high risk for carotid artery surgery. Clinical outcome data for Abbott's Emboshield BareWire(TM) Rapid Exchange Embolic Protection System and Xact Rapid Exchange Carotid Stent System and ACCULINK(TM) Carotid Stent System and ACCUNET(TM) Embolic Protection System will be reported.

Late-Breaking Clinical Trials III Press Conference at ACC

EXACT and CAPTURE 2 data will be included in the ACC late-breaking clinical trials III press conference at noon Central time on Monday, March 26, in Press Conference Room 215.

SPIRIT II One Year Clinical Results with 300 Patients

e-Poster Session 210 - Monday, March 26, 2 p.m. Central Time

Hall H, Ernest N. Morial Convention Center

One-year follow-up results from 300 patients in the SPIRIT II clinical trial will be presented in a poster session by Peter Ruygrok, M.D., cardiologist at Auckland City Hospital and Clinical Associate Professor at University of Auckland, New Zealand. This is the first time that long-term data will be presented from SPIRIT II, a 300-patient, randomized, single- blind, prospective clinical trial evaluating XIENCE V versus TAXUS in Europe and Asia Pacific. In addition, Abbott will also pres
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/9/2009)... 9 Bend Research Inc., a company,w...nnovative pharmaceutical,technologies to help clie...nical problems, announced today that it has entere... Incorporated, a global biotechnology company,head...s new collaboration, Vertex will utilize Bend,s fo...
(Date:11/8/2009)...e of Health Care Reform Bill ,, Critical legi...e for all Americans ,, BOISE, Idaho, Nov. 7 ... House of Representatives passed critical health c...are for seniors and end discrimination by insuranc...of affordable health coverage. ,, The Afforda...
(Date:11/6/2009)...ire-FirstCall/ -- Recession in domestic and intern...ied Healthcare Products in the first quarter of fi...les declines pushed Allied into a loss for the qua...,000, or negative 9 cents per share, compared to a... 3 cents per share. ,, Sales fell about 21 per...
Breaking Medicine Technology:Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3AARP Idaho Key Vote News Alert 2AARP Idaho Key Vote News Alert 3Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Smart for Life 28TM 29 Featured in Womans World Magazine 51752 1Smart for Life 28TM 29 Featured in Womans World Magazine 51752 2Oncolytics Biotech 28R 29 Inc Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 13038 1Oncolytics Biotech 28R 29 Inc Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 13038 2Cellular Dynamics International In Licenses Key Patent Portfolio for Using Stem Cell Derived Cells in Drug Testing 13037 1Cellular Dynamics International In Licenses Key Patent Portfolio for Using Stem Cell Derived Cells in Drug Testing 13037 2Cellular Dynamics International In Licenses Key Patent Portfolio for Using Stem Cell Derived Cells in Drug Testing 13037 3
...lts at 2007 American Association for,Cancer Resear...wswire-FirstCall/ -- Cleveland,BioLabs, Inc. , ann... CBLB502,s efficacy as a mitigator of both,gastroi...d,production) radiation-induced damage in non-huma..., Andrei Gudkov, Ph.D, D. Sci.,will present resul...
...ESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (LSE and ...ay announced data from Study 767905/014 and,provid...or,alvimopan (Entereg/Entrareg(R))., Study 014, a ...h) study, was designed to evaluate the long-term s...aily in patients taking,opioids for chronic non-ca...
Other Medicine Technology:Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 2Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:11/9/2009)...., Nov. 9 - The U.S. Cen...ntly awarded the Pennsylvania Coalition Against Ra...o continue funding its National Sexual Violence Re...he NSVRC since 2000 to serve as the nation,s princ...g, and sharing information and resources about all...
(Date:11/9/2009)... Madeleines to the overbearing food critic in the ...ildhood at the aroma of stew, artists have long be...trong memories. Scientists at the Weizmann Institu...is of this connection. Their research appeared in ...te student Yaara Yeshurun, together with Profs. No...
(Date:11/9/2009)...those hurt are under 16, researchers say , ...juries have skyrocketed in the United States in re... 2007, a new study has found. , However, the t...ategory that includes whirlpools and spas -- remai...ut half of the injuries were caused by slips and f...
(Date:11/9/2009)..., Nov. 9 Renewal Laboratories anno... process to produce functional beverages with impo...al, nutritionally important supplements such as Co...ow be offered in appealing and refreshing drinks. ... of all natural drinks that can help maintain card...
(Date:11/9/2009)... On Tuesday November 10th, at 5:30 pm CS...g a lecture on Radiation Therapy Options for Mesot...ia teleconference, and via the mesocare.org websit...s) November 9, 2009 -- Mesothelioma lecture on T...org is sponsoring a lecture by Veronica Garza of M...
Breaking Medicine News(10 mins):Health News:CDC Awards Vital Prevention Funding to National Sexual Violence Resource Center 2Health News:Sniffing out memories 2Health News:Hot-Tub Injuries on the Rise 2Health News:Renewal Laboratories(TM) Announces the First Omega3 Supplement Water for Cardiac Health 2
...vival increase according to stage of disease, a ne... issue of CANCER, a peer-reviewed journal of the A...f survival data demonstrates that within each stag...inical factors the racial disparities in survival ...
...ditorial, to be published in the international jou...sevierhealth.com/journals/joca/ ), published by El...recommended that coxibs and nonsteroidal anti-infl...an international workshop organized by the Osteoar...
...en a routine visit to the family doctor includes a...ing Alzheimer’s disease (AD). If the test returns ...ns that might begin to gum up memory and thought i...hers at Mayo Clinic’s campus in Jacksonville aims ...
...ts who do not respond to traditional therapy can b...l transplant, according to an Indiana University S...he New England Journal of Medicine. About 90 p...tment of this disease by Lawrence Einhorn, M.D., a...
...eached 'epidemic' levels for the second time in th...ay said. The Ministry of Health said 381 ...the 'epidemic threshold' of 378 cases per week. ... ministry said. Singapore experienced its ...
...rth of the first baby to be produced from an egg, ... and defrosted for later use. The news pr...failure or who cannot be administered drugs that h...ductive Centre in Montreal. The baby's mother has ...
Other Medicine News:Health News:Survival differences by race most apparent in advanced stages of breast cancer 2Health News:Using coxibs and NSAIDs to treat osteoarthritis 2Health News:A new century of Alzheimer's disease research 2Health News:A new century of Alzheimer's disease research 3Health News:A new century of Alzheimer's disease research 4Health News:A new century of Alzheimer's disease research 5Health News:A new century of Alzheimer's disease research 6Health News:A new century of Alzheimer's disease research 7Health News:A new century of Alzheimer's disease research 8Health News:A new century of Alzheimer's disease research 9Health News:A new century of Alzheimer's disease research 10Health News:A new century of Alzheimer's disease research 11Health News:A new century of Alzheimer's disease research 12Health News:A new century of Alzheimer's disease research 13Health News:A new century of Alzheimer's disease research 14Health News:A new century of Alzheimer's disease research 15Health News:A new century of Alzheimer's disease research 16Health News:A new century of Alzheimer's disease research 17Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:First Baby Born from Eggs Matured and Frozen in the Lab 2
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: